Skip to main content
. 2022 Nov 25;13:1042394. doi: 10.3389/fendo.2022.1042394

Figure 3.

Figure 3

The results of univariate logistic regression analysis of indicators associated with axillary pCR in the training set (N = 378) pCR, pathologic complete response; NST, neoadjuvant systemic therapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; EC-TH(P), epirubicin, cyclophosphamide followed by taxanes, trastuzumab and pertuzumab.